Janssen Korea may be ordered to suspend the production of two types of Tylenol syrup for children after the authorities found that the Korean unit of the U.S.-based drug maker violated pertinent regulations.
The scope of punishment could also be expanded, depending on the outcome of an ongoing special investigation. The two drugs account for 16 percent of the local market, amounting to 21.4 billion won in sales. Read the full story.